國立虎尾科技大學 |

Translational Pancreatic Cancer Research = From Understanding of Mechanisms to Novel Clinical Trials /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Translational Pancreatic Cancer Research/ edited by Christoph W. Michalski, Jonas Rosendahl, Patrick Michl, Jörg Kleeff.
Reminder of title:	From Understanding of Mechanisms to Novel Clinical Trials /
other author:	Michalski, Christoph W.
Description:	XII, 245 p. 18 illus., 17 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Oncology . -
Online resource:	https://doi.org/10.1007/978-3-030-49476-6
ISBN:	9783030494766

Translational Pancreatic Cancer Research = From Understanding of Mechanisms to Novel Clinical Trials /
Translational Pancreatic Cancer ResearchFrom Understanding of Mechanisms to Novel Clinical Trials /[electronic resource] :edited by Christoph W. Michalski, Jonas Rosendahl, Patrick Michl, Jörg Kleeff. - 1st ed. 2020. - XII, 245 p. 18 illus., 17 illus. in color.online resource. - Molecular and Translational Medicine,2197-7852. - Molecular and Translational Medicine,.

Subtypes of Pancreatic Adenocarcinoma -- Surveillance and Intervention in IPMN -- Novel Biomarkers of Invasive IPMN -- Challenges and Opportunities for Early Pancreatic Cancer Detection: Role for protein biomarkers -- Metabolic Biomarkers of Pancreatic Cancer -- Blood-Based Circulating RNAs as Preventive, Diagnostic, Prognostic and Drugable Biomarkers for Pancreatic Ductal Adenocarcinoma -- Circulating tumor DNA as a novel biomarker for pancreatic cancer -- PDAC Subtypes/Stratification -- Circulating Tumor Cells as Biomarkers in Pancreatic Cancer -- Personalized Models of Human PDAC -- Therapeutic Targeting of Stromal Components -- Epigenetic Targeting -- Targeting Metabolism -- Targeting the Immune System in Pancreatic Cancer -- Phase I Trials in Pancreatic Cancer -- Translational Approaches in Surgical Treatment.

This book incorporates a multi-disciplinary approach to present how research results can be translated into clinical trials. The first part begins with a chapter on variants of pancreatic cancer, precursor lesions and groups of people at risk to developing the disease. There is a particular focus on intraductal papillary mucinous neoplasia as a large-scale clinical challenge in pancreatology. The next two parts focus on diagnosis, biomarkers and stratification that emphasize how various approaches to biomarker development are important as both prognostic and predictive tools. The final part consists of personalized treatment approaches that include preclinical models of pancreatic cancer and stromal, epigenetic and metabolism targeting as promising approaches to be translated into early phase clinical trials. Chapters within this part also deal with approaches that are close to being implemented in clinical practice or are already being tested in (early) clinical trials, such as those that targeting the immune systems and strategies to overcome immunotherapy resistance; phase 1 clinical trials and translational approaches in surgical treatment. Written by experts in their fields, Translational Pancreatic Cancer Research provides an outlook towards future directions by integrating information both from basic and clinical research and though demonstrating pathways to better understanding pancreatic cancer and current approaches to translating these into clinical practice.

ISBN: 9783030494766

Standard No.: 10.1007/978-3-030-49476-6doiSubjects--Topical Terms:

1253469
Oncology .

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Translational Pancreatic Cancer Research = From Understanding of Mechanisms to Novel Clinical Trials /
LDR:03820nam a22004095i 4500 001 1017492
003 DE-He213
005 20200731172542.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783030494766 $9 978-3-030-49476-6
024 7 $a 10.1007/978-3-030-49476-6 $2 doi
035 $a 978-3-030-49476-6
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Translational Pancreatic Cancer Research $h [electronic resource] : $b From Understanding of Mechanisms to Novel Clinical Trials / $c edited by Christoph W. Michalski, Jonas Rosendahl, Patrick Michl, Jörg Kleeff.
250 $a 1st ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2020.
300 $a XII, 245 p. 18 illus., 17 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Molecular and Translational Medicine, $x 2197-7852
505 0 $a Subtypes of Pancreatic Adenocarcinoma -- Surveillance and Intervention in IPMN -- Novel Biomarkers of Invasive IPMN -- Challenges and Opportunities for Early Pancreatic Cancer Detection: Role for protein biomarkers -- Metabolic Biomarkers of Pancreatic Cancer -- Blood-Based Circulating RNAs as Preventive, Diagnostic, Prognostic and Drugable Biomarkers for Pancreatic Ductal Adenocarcinoma -- Circulating tumor DNA as a novel biomarker for pancreatic cancer -- PDAC Subtypes/Stratification -- Circulating Tumor Cells as Biomarkers in Pancreatic Cancer -- Personalized Models of Human PDAC -- Therapeutic Targeting of Stromal Components -- Epigenetic Targeting -- Targeting Metabolism -- Targeting the Immune System in Pancreatic Cancer -- Phase I Trials in Pancreatic Cancer -- Translational Approaches in Surgical Treatment.
520 $a This book incorporates a multi-disciplinary approach to present how research results can be translated into clinical trials. The first part begins with a chapter on variants of pancreatic cancer, precursor lesions and groups of people at risk to developing the disease. There is a particular focus on intraductal papillary mucinous neoplasia as a large-scale clinical challenge in pancreatology. The next two parts focus on diagnosis, biomarkers and stratification that emphasize how various approaches to biomarker development are important as both prognostic and predictive tools. The final part consists of personalized treatment approaches that include preclinical models of pancreatic cancer and stromal, epigenetic and metabolism targeting as promising approaches to be translated into early phase clinical trials. Chapters within this part also deal with approaches that are close to being implemented in clinical practice or are already being tested in (early) clinical trials, such as those that targeting the immune systems and strategies to overcome immunotherapy resistance; phase 1 clinical trials and translational approaches in surgical treatment. Written by experts in their fields, Translational Pancreatic Cancer Research provides an outlook towards future directions by integrating information both from basic and clinical research and though demonstrating pathways to better understanding pancreatic cancer and current approaches to translating these into clinical practice.
650 0 $a Oncology . $3 1253469
650 0 $a Pathology. $3 668553
650 1 4 $a Oncology. $3 593951
700 1 $a Michalski, Christoph W. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1312319
700 1 $a Rosendahl, Jonas. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1312320
700 1 $a Michl, Patrick. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1312321
700 1 $a Kleeff, Jörg. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1312322
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030494759
776 0 8 $i Printed edition: $z 9783030494773
776 0 8 $i Printed edition: $z 9783030494780
830 0 $a Molecular and Translational Medicine, $x 2197-7852 $3 1255156
856 4 0 $u https://doi.org/10.1007/978-3-030-49476-6
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)